Hafnia alvei: Difference between revisions

From IDWiki
Hafnia alvei
Content deleted Content added
No edit summary
No edit summary
 
(3 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{DISPLAYTITLE:''Hafnia alvei''}}

== Background ==
== Background ==


Line 12: Line 10:
== Management ==
== Management ==


* Reliably susceptible to [[imipenem]], [[ciprofloxacin]], [[piperacillin]], [[cotrimoxazole]][[CiteRef::gunthard1996cl]][[CiteRef::ramos2000ex]]
* Reliably susceptible to [[imipenem]], cefepime, [[ciprofloxacin]], aminoglycosides, [[cotrimoxazole]][[CiteRef::gunthard1996cl]][[CiteRef::ramos2000ex]][[CiteRef::bhardwaj2025ch]]
* May be susceptible to [[ceftriaxone]] and [[ceftazidime]] and [[amoxicillin-clavulanic acid]]
** Often susceptible to [[nitrofurantoin]][[CiteRef::CiteRef::lancelevee2007an]]
* May be susceptible to [[ceftriaxone]] and [[ceftazidime]], but may have inducible resistance[[CiteRef::lancelevee2007an]]
* Unreliably susceptible to cephalothin and [[amoxicillin-clavulanic acid]] and [[piperacillin]][[CiteRef::bhardwaj2025ch]][[CiteRef::lancelevee2007an]]


[[Category:Gram-negative bacilli]]
[[Category:Gram-negative bacilli]]
{{DISPLAYTITLE:''Hafnia alvei''}}

Latest revision as of 12:47, 20 June 2025

Background

  • Gram-negative bacillus in the genus Hafnia
  • Rare cause of disease in humans

Clinical Manifestations

  • Can cause bacteremia, gastroenteritis, meningitis, pneumonia, nosocomial wound infections, hepatobiliary infections, psoas abscess, prosthetic valve endocarditis, and endophthalmitis12

Management

References

  1. ^  H. Gunthard, A. Pennekamp. Clinical Significance of Extraintestinal Hafnia alvei Isolates from 61 Patients and Review of the Literature. Clinical Infectious Diseases. 1996;22(6):1040-1045. doi:10.1093/clinids/22.6.1040.